WellStar Health System
Welcome,         Profile    Billing    Logout  
 0 Trials 
5 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
George, Marjorie Patricia
CAPACITY, NCT04084678: A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH

Terminated
3
10
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Hypertension, Connective Tissue Disease, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease, Pulmonary Arterial Hypertension
04/23
04/23
IMPAHCT, NCT05036135 / 2021-001910-13: A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

Terminated
2/3
202
Europe, Canada, US, RoW
AV-101, Placebo
Aerovate Therapeutics, Aerovate Therapeutics, Inc.
Pulmonary Arterial Hypertension
08/24
08/24
NCT05977933: Assessing the Utility of Submaximal CPET in Treatment Management of PAH

Not yet recruiting
N/A
550
US
Shape II CPET
Shape Medical Systems, Inc., National Heart, Lung, and Blood Institute (NHLBI)
Pulmonary Arterial Hypertension
09/24
12/24
Guichard, Paul
NCT05977933: Assessing the Utility of Submaximal CPET in Treatment Management of PAH

Not yet recruiting
N/A
550
US
Shape II CPET
Shape Medical Systems, Inc., National Heart, Lung, and Blood Institute (NHLBI)
Pulmonary Arterial Hypertension
09/24
12/24
Pickens, Brandon D
NCT05977933: Assessing the Utility of Submaximal CPET in Treatment Management of PAH

Not yet recruiting
N/A
550
US
Shape II CPET
Shape Medical Systems, Inc., National Heart, Lung, and Blood Institute (NHLBI)
Pulmonary Arterial Hypertension
09/24
12/24

Download Options